Back to results

(AZN)

Buy:
12,108.00 p
Sell:
12,104.00 p
Change:
-118.00 (-0.96%)
Open an account

AstraZeneca (AZN)

AstraZeneca

ISIN:

GB0009895292

Sector:

Pharmaceuticals & Biotechnology

Trading on:

London Stock Exchange

Buy:
12,108.00 p
Sell:
12,104.00 p
Change:
-118.00 (-0.96%)
Updated at: 24-08-2026 - 16:36
*Prices delayed by at least 15 minutes
At a glance

At a glance performance and information

Trading update:

Opening price:

12,182.00 p

Previous close:

12,110.00 p

Day High / Low:

12,204.00 p - 12,016.00 p

52 week High / Low:

15,316.00 p - 10,956.00 p

Volume:

1,762,163

Fundamentals:

Market capitalisation (m):

£ 187,830.14

Shares in issue (m):

1,551

P/E ratio / PEG:

25.97 / 0.57

EPS:

N/A

Currency:

GBP

Dividends:

Last dividend:

USX 217.0000 (23/03/2026)

Dividend yield:

1.87%

Next dividend:

USX 106.0000 (08/09/2026)

Ex-Dividend date:

06/08/2026

Click to see dividend history

Eligibility:

Share Dealing Account
ISA
SIPP

Investing for longer increases the likelihood of positive returns. Over a period of 5 years or more, investments usually give you a higher return compared to cash savings. But investments can go down as well as up in value. So you could get back less than you put in.

Intraday 1 W 1 M 3 M 6 M YTD 1 Y 3 Y 5 Y Max
Advanced Chart
Recent Trades
Dividends
Financials

In the news

image of the news AstraZeneca posts mixed lung‑cancer trial updates
AstraZeneca posts mixed lung‑cancer trial updates
image of the news AstraZeneca, Bristol Myers Squibb in talks over $400bn tie-up - report
AstraZeneca, Bristol Myers Squibb in talks over $400bn tie-up - report
image of the news AstraZeneca reports first-half growth, disappointment in Ultomiris trial
AstraZeneca reports first-half growth, disappointment in Ultomiris trial
image of the news AstraZeneca breast cancer drug receives EU approval
AstraZeneca breast cancer drug receives EU approval
image of the news Astrazeneca strikes exclusive licensing deal with Dizal Pharmaceutical
Astrazeneca strikes exclusive licensing deal with Dizal Pharmaceutical
image of the news AstraZeneca shares slide on failure of cardiomyopathy trial
AstraZeneca shares slide on failure of cardiomyopathy trial
image of the news AstraZeneca's Datroway and Enhertu candidates receive EU approval
AstraZeneca's Datroway and Enhertu candidates receive EU approval
image of the news Astrazeneca secures US approval for Truqap combo in PTEN‑deficient prostate cancer
Astrazeneca secures US approval for Truqap combo in PTEN‑deficient prostate cancer
image of the news Astrazeneca's Imfinzi receives green light from US FDA
Astrazeneca's Imfinzi receives green light from US FDA
image of the news US FDA pushes back decision on Astrazeneca's camizestrant
US FDA pushes back decision on Astrazeneca's camizestrant
image of the news Astrazeneca's Camizestrant cleared in the EU, Enhertu and Datroway pick up fresh recommendations
Astrazeneca's Camizestrant cleared in the EU, Enhertu and Datroway pick up fresh recommendations
image of the news Citi sees buying opportunity at AstraZeneca after recent falls
Citi sees buying opportunity at AstraZeneca after recent falls
image of the news AstraZeneca secures US approval for two drugs
AstraZeneca secures US approval for two drugs
image of the news AstraZeneca reports positive results from bladder cancer drug trial
AstraZeneca reports positive results from bladder cancer drug trial
image of the news AstraZeneca Q1 revenues grow, reiterates FY26 constant currency guidance
AstraZeneca Q1 revenues grow, reiterates FY26 constant currency guidance
image of the news AstraZeneca's asthma maintenance treatment receives US FDA approval
AstraZeneca's asthma maintenance treatment receives US FDA approval
image of the news AstraZeneca's Saphnelo Pen gets green light from US FDA
AstraZeneca's Saphnelo Pen gets green light from US FDA
image of the news AstraZeneca receives positive high level results from Phase III I CAN trial
AstraZeneca receives positive high level results from Phase III I CAN trial
image of the news AstraZeneca reports positive top-line data from Phase III MIRANDA trial
AstraZeneca reports positive top-line data from Phase III MIRANDA trial
image of the news AstraZeneca upbeat on results of liver cancer treatment trial
AstraZeneca upbeat on results of liver cancer treatment trial
image of the news AstraZeneca drug for rare bone disease shows positive trial results
AstraZeneca drug for rare bone disease shows positive trial results
image of the news AstraZeneca's COPD candidate succeeds in twin Phase III studies
AstraZeneca's COPD candidate succeeds in twin Phase III studies
image of the news Astrazeneca's Imfinzi receives EU approval
Astrazeneca's Imfinzi receives EU approval
image of the news AstraZeneca's Calquence leukaemia treatment gets US FDA approval
AstraZeneca's Calquence leukaemia treatment gets US FDA approval
image of the news Shore Capital lowers AstraZeneca to 'hold'
Shore Capital lowers AstraZeneca to 'hold'
image of the news Annual sales, profits jump at AstraZeneca
Annual sales, profits jump at AstraZeneca
image of the news FDA rejects self-injectable version of AstraZeneca lupus drug
FDA rejects self-injectable version of AstraZeneca lupus drug
image of the news Astrazeneca's Imfinzi receives EU recommendation from CHMP
Astrazeneca's Imfinzi receives EU recommendation from CHMP
image of the news AstraZeneca strikes collaborative agreement with CSPC Pharmaceuticals
AstraZeneca strikes collaborative agreement with CSPC Pharmaceuticals
image of the news AstraZeneca unveils $15bn China investment
AstraZeneca unveils $15bn China investment
image of the news Citi starts AstraZeneca at 'buy', takes 'neutral' stance on GSK
Citi starts AstraZeneca at 'buy', takes 'neutral' stance on GSK
image of the news AstraZeneca gets fresh designation for Enhertu while Imfinzi trial fizzles
AstraZeneca gets fresh designation for Enhertu while Imfinzi trial fizzles

RNS

image of the news Director/PDMR Shareholding
Director/PDMR Shareholding
image of the news Enhertu improved PFS in 1L HER2m lung cancer
Enhertu improved PFS in 1L HER2m lung cancer
image of the news Update on eVOLVE-Lung02 Phase III trial
Update on eVOLVE-Lung02 Phase III trial
image of the news Tagrisso+Orpathys improved PFS & OS in EGFRm lung
Tagrisso+Orpathys improved PFS & OS in EGFRm lung
image of the news Admission of Further Securities to Trading
Admission of Further Securities to Trading
image of the news Total Voting Rights
Total Voting Rights
image of the news Datroway approved in EU for TNBC
Datroway approved in EU for TNBC
image of the news Update on Ultomiris Phase III trial in HSCT-TMA
Update on Ultomiris Phase III trial in HSCT-TMA
image of the news Sone-Ve improved survival in gastric cancers
Sone-Ve improved survival in gastric cancers
image of the news Half-year Financial Report
Half-year Financial Report